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David Aharonoff

IS THERE A GENETIC BASIS FOR ALCOHOLISM?
ABSTRACT

David Aharonoff

This paper reviews studies done on the correlation of alcoholism and genetics.
Evidence of this correlation can be seen in high heritability of alcoholism. The main methods
used in determining genetic risk factors are candidate gene studies and genome wide studies.
This review focuses mainly on findings related to specific neurotransmitters and receptors in
relation to alcoholism. Evidence has shown that specific neurotransmitters and receptors can
play a role in increased susceptibility to alcoholism. The neurotransmitters and receptors
discussed in this paper include GABA, glutamate, and endogenous opioids. There is also a
discussion focused on mutations of specific enzymes (ADH and ALDH) used to metabolize
alcohol and its possible effects on developing alcoholism. When applicable, findings include a
potential pharmacological treatment targeting the possible causation for alcoholism. Results
from the studies conducted by the Collaborative Studies on Genetics of Alcoholism (COGA)
have been discussed as well. COGA findings include specific chromosomes and their
relationships with alcoholism, namely 1, 4 , 7, 11, and a possible indicator for increased
susceptibility, or level of response (LR).
The World Health Organization (WHO) estimates that alcohol results in 2.5 million
deaths each year and in 9% of all deaths between the ages of 15 and 29. The WHO further
concludes that alcohol is the world’s third largest risk factor for disease burden; it is the
leading risk factor in the Western Pacific and the Americas, and the second largest in Europe
(World Health Organization 2011). An American survey by Hasin and colleagues (2007)
concludes that alcoholism affects 4-5 % of the population at any given time. As a result of these
widespread ramifications, alcoholism has been a subject of much research. This paper will
primarily deal with the studies of genetic influences that affect alcoholism risk. Locating a
genetic link can lead to possible alcoholism prevention of those genetically susceptible and help
better treat those who have already developed the problem.
DISCUSSION

In order for researchers to compare and contrast their findings, they must agree
on the definition of an alcoholic. Most researchers rely on the definition of the
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, [DSM-IV]
(APA 1994) and the World Health Organization’s International Classification of
Diseases (ICD-10). The Diagnostic and Statistical Manual of Mental Disorders of the
American Psychiatric Association, fourth edition (DSM-IV) defines alcohol
dependence, to be equated with alcoholism, as:
A maladaptive pattern of substance use, leading to clinically significant
impairment or distress, as manifested by three (or more) of the
following, occurring at any time in the same 12-month period:
1. Tolerance, as defined by either of the following:
• A need for markedly increased amounts of the substance to achieve
intoxication or desired effect.
• Markedly diminished effect with continued use of the same amount of
substance.
2. Withdrawal, as manifested by either of the following:
• The characteristic withdrawal syndrome for the substance.
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• The same (or a closely related) substance is taken to relieve or avoid
withdrawal symptoms.
3. The substance is often taken in larger amounts or over a longer period
than was intended.
4. There is a persistent desire or unsuccessful efforts to cut down or
control substance use.
5. A great deal of time is spent in activities to obtain the substance, use
the substance, or recover from its effects.
6. Important social, occupational or recreational activities are given up
or reduced because of substance use.
7. The substance use is continued despite knowledge of having a
persistent or recurrent physical or psychological problem that is likely to
have been caused or exacerbated by the substance (e.g., continued
drinking despite recognition that an ulcer was made worse by alcohol
consumption).
The ICD-10 criteria for alcoholism are similar to that of the DSM-IV (Baber
1992). A main difference is that ICD-10 doesn’t include a category on alcohol abuse,
but rather refers to the same diagnosis as “harmful use.” The change is meant to
prevent an underreporting of alcohol abuse (Baber 1992). “Harmful use” includes
psychical or mental damage due to alcohol dependence (Baber 1992).
A possible indication that a genetic predisposition for alcoholism exists is the
fact that an alcoholic’s biological offspring are approximately three to five times more
likely to develop alcoholism during their lifetime than the biological offspring of
nonalcoholics (Cotton 1979). One can argue, however, that the increased rate of
alcoholism in alcoholics’ biological offspring is due to environmental influences; a
positive family history can merely be the result of shared environmental influences.
Therefore, behavioral geneticists use twin and adoption studies to identify the separate
contributions of genetics and shared environmental factors.
Researchers use analyses of genetically identical monozygotic twins (MZ) and
fraternal dizygotic (DZ) twins to measure the heritability of alcoholism. There are
eight major twin studies of alcoholism in men, and in all but one of these studies the
concordance (same trait in both members of a pair of twins) rate for alcoholism was
significantly greater in MZ than DZ twins (McGue1999). For example, in a study by
Kendler, Prescott, Neale, and Pedersen (1997) on 8,939 Swedish male twins born from
1902 to 1949, the MZ twin concordance rate is significantly higher than the DZ twin
concordance rate. Overall, the studies’ concordance rates in monozygotic twins are
approximately 47.9%, and in dizygotic twins, 32.8%.
Adoption studies also allow researchers to better separate genetics from
environmental influences on the development of alcoholism. Seminal research by
Cloninger and colleagues (1987) uses a large-scale adoption study in Sweden to
identify genetic and other variables that predict alcohol abuse in adoptees. This study,
coined the Stockholm Adoption Study, was done on 862 men and 913 women adopted
by non-relatives at an early age in Sweden. The study distinguishes between two
forms of alcoholism: Type I is characterized as late onset of alcoholism, after age 25,
and marked by frequent psychological dependence; Type II alcoholism is
characterized as a relatively early onset of alcoholism, before age 25, and marked by
spontaneous alcohol seeking and aggressive behavior. Analysis of data from male
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adoptees shows that although Type II alcoholism has an approximate heritability of
90%, Type I alcoholism has a heritability estimate of less than 40%. Many of the key
results from the original Stockholm Adoption Study were independently replicated in
a second Swedish city, Gothenburg (Sigvardsson et al. 1996). The replication study
was carried out on a slightly smaller group (577 men and 660 women) but concludes
that the risk of Type 2 alcoholism is increased 6-fold in adopted sons with a Type 2
genetic background compared with others, while Type I alcoholism has only a 4-fold
increase in adopted men with Type I genetic backgrounds of alcoholism.
Due to the evidence that alcoholism is heritable, the next step is to identify the
possible genetic factors that lead to the heritability. Two basic strategies are used to
identify genetic risk factors for alcoholism: candidate gene approach and genome-wide
studies (Sloan et al. 2008). The candidate gene approach involves assessing the
association between a particular allele (or set of alleles) of a gene that may be involved
in the disease (i.e. a candidate gene) and the disease itself (Kwon and Goate 2000).
This approach often begins with the knowledge of potential physiological mechanisms
that might be related to the endophenotype and makes educated guesses about which
of the known genes might be important (Schuckit 2000). The genes most extensively
examined by candidate gene studies are those involved in alcohol (i.e. ethanol)
metabolism and in neurological pathways responsible for increased risk taking and
“reward” stimulation from ethanol (Sloan et al. 2008).
A genome-wide study scans all genomes of individuals and identifies genetic
polymorphisms. The two main approaches to genome-wide analysis are association and
linkage (Sloan et al. 2008). Association studies examine genetic polymorphisms
associated with case or control status, whereas linkage studies investigate the
inheritance of specific locations on a chromosome within family lines (Sloan et al.
2008). In association studies, one tests if a given allele contributes to the risk for
alcohol dependence. For example, if a researcher hypothesizes that Gene A plays a role
in alcoholism, he would expect this allele to differ between the case and the control
subjects.
Linkage analysis scans the genome using a type of genetic variation called
microsatellites. Microsatellites are nucleotide pair combinations of DNA which repeat
themselves and form groupings. Microsatellites can be highly polymorphic, making
them useful for comparative genetic studies of organisms. Then, the pattern of
transmission of disease (e.g. alcoholism) in families with multiple affected members is
compared with the pattern of transmission of certain microsatellites (Foroud et al.
2010). The principal hypothesis in linkage analysis is that alcoholics within a family
share many risk alleles; therefore, genes containing alleles that increase the risk for
alcoholism reside within chromosomal regions that are inherited by most or all
alcoholic family members (Foroud et al. 2010).
A prime example of specific genes related to the risk of alcoholism are those
that control the production of the enzymes that metabolize ethanol (i.e. alcohol).
Ethanol is metabolized in the liver, where it is converted to acetaldehyde by the
enzyme alcohol dehydrogenase (ADH). ADH is responsible for 80% of ethanol’s
metabolism to acetaldehyde (Gemma et al. 2006). About 10% of ethanol is metabolized
by CYP2E1; the percentage increases when ADH is saturated (Gemma et al. 2006).
Acetaldehyde is then converted to acetate by the enzyme aldehyde dehydrogenase
(ALDH). High levels of acetaldehyde in the blood causes nausea, dizziness, and

Is There a Genetic Basis for Alcoholism?

17

headaches; therefore, variation in the genes coding for the ADH and ALDH enzymes
are expected to be associated with alcoholism risk (Edenberg 2007).
There are at least six isoenzymes of ALDH (Schuckit 2000). ALDH2*2, an
isoenzyme of ALDH, involves a point mutation that results in the exchange of the
amino acid glutamate at position 487 of the ALDH protein for the amino acid lysine
(Edenberg 2007; Foroud et al. 2010). This mutation acts in a nearly dominant manner
to render the enzyme almost inactive (Foroud et al. 2010). As a result, homozygous
carriers of ALDH2-2 exhibit highly elevated levels of acetaldehyde, which produces
aversive reactions, including flushing, tachycardia and nausea after consuming even a
small amount of alcohol (Eng et al. 2007). Studies have shown that ALDH2-2
influences a person’s drinking levels, and, consequently, the risk of developing alcohol
abuse or dependence (Edenberg 2007; Hurley et al. 2002). There are almost no
documented cases of homozygous carries of ALDH2-2 being diagnosed as alcoholics
(Luczak et al. 2006). Even people who are heterozygous for this mutation produce an
ALDH enzyme with extremely low enzyme activity (Crabb et al. 1989).
Approximately 10% of Asian men and women (e.g. Japanese, Chinese, and
Koreans) are homozygous for the mutation of ALDH2*2, although it is not known to
be found in any other racial group (Wall and Ehlers 1995). An additional 40% of
Asians are heterozygotes for the ALDH mutated enzyme (Wall and Ehlers 1995).
Compared with a Chinese man carrying two active ALDH alleles, the odds ratio of an
alcoholism risk for a Chinese man carrying one inactive ALDH2-2 allele is 0.33
(Edenberg 2007). Furthermore, although heterozygote ALDH2-2 carriers represent
almost half of the general population in their countries, they comprise less than 10% of
Asian alcoholics, further supporting the conclusion that even heterozygotes have a
relative protection from alcoholism (Murayama et al. 1998).
There are also coding variations in the ADH gene, called ADH2-2 and ADH23, which encode highly active enzymes which increase the production rate of
acetaldehyde (Li 2000). These variations also reduce the risk for alcohol dependence
(Edenberg 2007; Thomasson et al. 1991). For example, a pilot study by Neumark and
colleagues (1998) was the first example of association between alcohol consumption
patterns and a polymorphism at the ADH2 locus in a Jewish population. The study
compares ADH loci in 92 non-drinkers (control) versus 53 heavy drinkers
(case). Neumark furthered the study in 2004 by testing the effect of ADH2-2 on
alcohol-elimination rates (AER) under experimental conditions. The study is based on
the above-cited hypothesis that ADH2-2 increases the rate at which alcohol is
metabolized, thereby increasing the production rate of acetaldehyde and producing
aversive reactions. The study confirms that the rate of alcohol elimination is
significantly associated with the ADH2 genotype of Jewish males (Neumark 2004).
The evidence that an increase of acetaldehyde can be a deterrent to the
development of alcohol abuse has led researchers to develop pharmacological
treatments. Disulfiram blocks the enzyme aldehyde dehydrogenase, leading to an
accumulation of acetaldehyde following an intake of alcohol (Heilig and Egli 2006).
The accumulation of acetaldehyde then causes flushing, shortness of breath,
tachycardia and other unpleasant symptoms. The point of disulfiram is not that
patients actually experience adverse symptoms, but that that the anticipation of these
symptoms helps patients abstain from consuming alcohol (Heilig and Egli 2006). The
logic is that an accumulation of acetaldehyde poses a possible medical risk. However,
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disulfiram has a limited and largely negative documentation for efficacy (Heilig and
Egli 2006). For example, a controlled multisite study of disulfiram treatment of
alcoholism in 605 men concludes that although disulfiram may help reduce drinking
frequency after relapse, it does not reduce the probability of abstinence from alcohol
(Fuller et al. 1986).
Researchers have also done candidate gene studies on genes for receptors in the
neurotransmitter gamma-aminobutyric acid (GABA), opioid receptor and components
of the pathways for the neurotransmitters serotonin, dopamine, and glutamate (Sloan
et al. 2008). A full discussion of each neurotransmitter surpasses the scope of this
paper; therefore, but a few neurotransmitters and receptors and their relation to
alcoholism will be discussed.
There is evidence supporting a link between the endogenous opioid system and
excessive alcohol consumption (Gianoulakis 2001; Herz 1997). This evidence, linking
the endogenous opioid system to alcoholism, led to several theories regarding the
possible nature of an opioid abnormality in this disorder (Oswald and Wand 2004).
The Opioid Deficit Hypothesis postulates that physiological cravings for alcohol may
be the result of a deficiency of naturally occurring opiate like substances
(Trachtenberg and Blum 1987). Conversely, the Opioid Surfeit Hypothesis maintains
that excess (i.e. surfeits), not deficits, in opioidergic activity increases one’s propensity
to consume alcoholic beverages (Reid et al. 1991).
The first study to suggest a possible link between endogenous opioid and
ethanol was conducted by Davis and Walsh (1970), who discovered that morphinelike alkaloids (tetrahydroisoquinolones) are formed in vivo as a result of the
interaction between ethanol metabolite, acetaldehyde, and certain metabolites of
dopamine. Due to Davis and Walsh’s findings, further research sought to demonstrate
that these alkaloids could bind to opioid receptors and produce opioid-like effects
(Blum et al. 1978; Fertel et al. 1980). However, the pharmacological relevance of these
compounds in opioidergic processes remains unclear because their concentrations in
brain tissues is extremely low (Oswald and Wand 2004).
The best evidence of the linkage between endogenous opioid systems and
ethanol consumption is that pharmacological blockades of opioid receptors
reduce alcohol drinking in a dose-related fashion. Naltrexone is an opioid receptor
antagonist that reduces alcohol cravings and relapses to heavy drinking, but it does not
necessarily produce total abstinence. The initial study done by Altshuler and
colleagues (1980) reports on the dose-related effect of naltrexone on decreasing
ethanol drinking in 10 of 21 rhesus monkeys who were willing to self-administer
alcohol. The treatment results were replicated by O’Malley et al. in 1992. In a 12week, double-blind, placebo-controlled trial conducted on seventy male alcoholdependent patients, Volpicelli and colleagues (1992) found that only 23% of alcoholic
subjects who were administered naltrexone relapsed to heavy drinking, compared with
54.3% of subjects taking a placebo. Based, in part, on the findings of these studies,
naltrexone was approved by the Food and Drug administration (FDA) in 1995 for the
treatment of ethanol dependence. Since naltrexone's approval for the treatment of
alcoholism, the opioid antagonist has been tested in 29 controlled clinical trials in
unselected participants with alcoholism (Pettinati et al. 2006). The study concludes
that “19 (70%) of 27 clinical trials that measured reductions in ‘heavy or excessive
drinking’ demonstrated an advantage for prescribing naltrexone over placebo, whereas
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only 9 (36%) of 25 clinical trials that measured abstinence or ‘any drinking’ found an
advantage for medication over placebo” (Pettinati et al. 2006).
The effects of naltrexone have led to candidate gene studies on opioid
receptors. There are three types of opioid receptors (mu, delta and kappa) that
represent respective targets of the major opioid peptides (Herz 1997). Naltrexone acts
as an antagonist at opioid receptors, with a relative selectivity for the µ-opioid receptor
(Oswald and Wand 2004). There are more than 25 identified allelic variants of the
gene that codes for the µ-opioid receptor (O’Brien 2008). In a human laboratory study
(Ray and Hutchison 2004), volunteers with Asp40 allele (OPRM1) reported greater
subjective euphoria at a given ethanol blood level. In a more recent study of heavy
drinkers, naltrexone attenuated the increased alcohol stimulation in those carrying the
Asp40 allele (Ray and Hutchison 2007).
Additionally, GABAergic mechanisms mediate many of the behavioral effects
of ethanol, including its anticonvulsant, sedative-hypnotic, cognitive-impairing, and
fine motor skill damaging effects (Kumar et al. 2009). The two classes of GABA
receptors are GABA-A and GABA-B. GABA-A receptors are ligand-gated ion
channels (i.e. ionotropic) that confer fast synaptic inhibition (Enoch 2007). GABA-A
receptors undergo allosteric modulation by several structurally unrelated drugs, most
with their own binding sites, including ethanol and benzodiazepines (Enoch 2007).
Initial evidence that alcoholism is related to GABA-A receptors is because
benzodiazepines show effectiveness in treating alcohol withdrawal (Enoch 2007).
GABA-A receptors are composed of five subunits (Sigel et al. 2006). Most
receptors consist of two ! (alpha), two " (beta), and one # (gamma) subunits (Sigel et
al. 2006). The GABA-A receptor ion channel is lined by the transmembrane (TM)
segments from each of the five subunits that form the receptor (Enoch 2007). Specific
mutations in transmembrane domains 2 and 3 of the alpha subunit can abolish or
markedly reduce the effects of ethanol on these receptors without necessarily affecting
receptor function; therefore, alcohols may bind in a cavity located between TM2 and
TM3 (Mascia et al. 2000).
Topiramate, which has a complex effect on GABA-A receptors, is
hypothesized to decrease alcohol reinforcement and the propensity to drink (Johnson
et al. 2007). A double-blind, randomized, placebo-controlled, 14-week trial of 371 men
and women concludes that “topiramate was significantly more efficacious than placebo
at reducing the percentage of heavy drinking days,” and “topiramate is a safe and
consistently efficacious medication for treating alcohol dependence”( Johnson et al.
2007).
GABA inhibits hypothalamic-pituitary–adrenal axis responses to stress whereas
glutamate activates the response (Herman et al. 2004). Prime targets of ethanol are the
N-methyl-D-aspartate (NDMA) receptors in the glutamate system (Spanagel 2009).
NMDA is an amino acid derivative that acts as a specific agonist at the NMDA
receptor, mimicking the action of glutamate. Acute alcohol exposure inhibits the
excitatory action of glutamate at the N-methyl-d-aspartate (NMDA) receptor,
whereas chronic alcoholism results in increased NMDA receptor expression so that
abrupt withdrawal produces a hyperexcitable state that leads to seizures
(Guochuan and Coyle 1998). These finding have led to the formulation of the
glutamate homeostasis hypothesis of addiction which suggests that enhanced
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glutamate-mediated neuronal excitability during withdrawal and prolonged abstinence
contributes to craving and relapse (Kalivas 2009).
Further, “Metabotropic glutamate (mGlu) receptors, which include mGlu1–8
receptors, are a heterogeneous family of G-protein-coupled receptors which function
to modulate brain excitability via presynaptic, postsynaptic and glial mechanisms”
(Schoepp 2001). In contrast to ionotropic receptors, metabotropic receptors influence
the activity of a cell indirectly by first initiating a metabolic change in the cell. Studies
provide evidence that activation of group II mGluRs (predominantly presynaptical) by
a selective mGlu 2/3 agonist (LY379268) dose dependently blocks the effects of both
stress and drug related environmental stimuli on the recovery of extinguished ethanolseeking behavior (Zhao et al. 2006). A similar study on group I mGluRs
(predominantly located postsynaptically) in alcohol-preferring P-rats, a well-defined
genetic model of excessive alcohol consumption, shows that infusion of the mGluR5
antagonist 2-methyl-6(phenylethynyl) pyridine (MPEP) in the nucleus accumbens
reduces ethanol-reinforced responding (Besheer et al. 2010). Besheer et al. (2010)
concludes that the data “confirms the importance of mGluR5 activity in the nucleus
accumbens in regulating drug reinforcement and emphasizes the potential therapeutic
utility of targeting this receptor system in individuals with genetic risk for excessive
drinking.”
The interaction of ethanol and glutamate led to candidate gene studies on
glutamate. An association study that tested the candidate gene hypothesis of allelic
variants of the ionotropic glutamatergic N-methyl-D-aspartate receptor (NMDAR)
provides evidence that they are associated with vulnerability to alcoholism (Wernicke
et al. 2003). Wernicke and colleagues studied variants of the ionotropic
glutamatergic N-methyl-d-aspartate receptor (NMDAR the silent G2108A and
C2664T polymorphisms of the NMDAR1 and the NMDAR2B genes), in exon 5 of
the EAAT2 gene in 702 subjects of German descent, comprising 367 alcoholdependent subjects and 335 control subjects. Genotype frequencies of the NMDAR1
polymorphism differed significantly between control and alcoholic subjects and the
NMDAR2B polymorphism revealed a significantly reduced T allele in Cloninger type
2 alcoholics and in patients reporting an early onset compared with control subjects.
In 1989, the National Institute on Alcohol Abuse and Alcoholism initiated the
Collaborative Study on the Genetics of Alcoholism (COGA), a large, systematic effort
to identify the genes that predispose to alcoholism. COGA’s goal is to elucidate the
genetic mechanisms that contribute to a person’s susceptibility to alcohol abuse and
dependence (Begleiter et al. 1995). COGA generated a dataset of 1,857 families
consisting of 16,062 individuals as of March 2010 (Foroud et al. 2010). Due to the
genetic complexity of alcoholism, COGA researchers chose an unbiased survey of the
entire genome (i.e. genotyping) (Edenberg 2002). Using microsatellite markers, more
than 1.2 million genotypes were generated on 2,310 people from families of alcoholics
and 1,238 people from control families (Edenberg 2002). This information enables
researches to monitor the inheritance pattern of marker alleles within families with
alcoholics and therefore helps identify chromosomal regions that show genetic linkage
with alcoholic related traits (Edenberg 2002). To be categorized as a “family of
alcoholics” the family must comprise at least three first-degree relatives who met
lifetime criteria for Diagnostic and Statistical Manual of Mental Disorders, Third Edition,
Revised (DSM–III–R) (Foroud et al. 2010).
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COGA data collected from families with alcoholism are used for both linkage
and association analyses (Sloan et al. 2008). In 1998, COGA researchers published
their initial linkage findings based on an analysis of 291 markers in 987 individuals
from 105 families (Reich et al. 1998). Substantial evidence points to a susceptibility loci
for alcohol dependence on chromosomes 1 and 7. In addition, there is suggestive
evidence for a protective locus on chromosome 4 near the ADH gene (Reich et al.
1998). At the same time as the COGA findings were published, a second large-scale
linkage study of alcoholism, based on a sample of Native Americans, reported
suggestive evidence of the existence of a predisposing gene on Chromosome 11p, in
close proximity to the DRD4 dopamine receptor (Long et al 1998). Evidence also
suggests a protective gene on Chromosome 4p, near the beta1 GABA receptor gene
(Long et al. 1998). Although only the Chromosome 4 findings overlapped, the two
studies sampled different ethnic groups, and the genes that underlie alcoholism risk
might be expected to vary for groups having distinct evolutionary history (McGue
1999). A more recent COGA study by Yang and colleagues (2005) found potential
candidate regions on chromosomes 1, 2, and 7 linked with alcoholism susceptibility.
Overall, Yang viewed his findings as consistent with Reich’s findings (Yang et al.
2005).
Due to prior evidence for the role of the ADH genes in alcoholism
susceptibility, the COGA investigators did several studies to determine the specific
nature of the link (Foroud et al. 2010). In one particular study, COGA researches
genotyped 110 DNA markers known as single nucleotide polymorphisms (SNPs)
across the seven ADH genes located on chromosome 4q and analyzed their association
with alcoholism in a set of families (n= 262) with multiple alcoholic members
(Edenberg et al. 2006). The analyses show strong evidence that 12 SNPs located in
and around the ADH4 gene are significantly associated with alcoholism (Edenberg et
al. 2006).
Evidence of a molecular interaction between ethanol and GABA receptors led
COGA researchers to study the link between variation in GABA receptors and
alcoholism. Edenberg and colleagues (2004) performed a linkage analyses of 69 singlenucleotide polymorphisms (SNPs) within a cluster of four GABA (A) receptor genes
located in chromosome 4p: GABRG1, GABRA2, GABRA4, and GABRB1. The
analyses found thirty-one SNPs in GABRA2 associated with alcohol dependence.
Edenberg concludes his study by stating, “ the convergence of evidence from different
analyses and phenotypes, along with the biological data on its function, provides
strong evidence that GABRA2 is a key gene affecting the risk for alcoholism.”
Interestingly, the GABRA2 is part of the GABA-A ! subunit that was mentioned
before as a possible binding spot for alcohol.
The genome-wide association studies (GWAS), also known as the whole
genome association studies, are examinations of all or most of the genes (the genome)
of different individuals of a particular species to see how much the genes vary from
individual to individual. Different variations are then associated with different traits,
such as diseases. In humans, hundreds or thousands of individuals are tested for
single-nucleotide polymorphisms (SNPs). The advantage of GWAS is that it allows a
comprehensive test for associations across the genome, rather than testing only one
gene at a time.

22

David Aharonoff

The genome-wide association studies (GWAS) examine up to a millions SNPs
through the human genome in a single experiment (Foroud 2010). The different
variations of SNPs between individuals is then associated with different traits, such as
diseases. An advantage of GWAS is its hypothesis-free strategy and its suitability for
the discovery of novel genetic contributors to disease (Bierut et al. 2010).
This first genome-wide significant association study in alcohol dependence was
published in 2009 (Treutlein et al. 2009). The GWAS included 487 male inpatients
with alcohol dependence as defined by the DSM-IV and 1,358 population-based control
individuals (Treutlein et al. 2009). The GWAS tested 524 396 singlenucleotide polymorphisms (SNPs) (Treutlein et al. 2009). The analyses found two
closely linked SNPs located on chromosome 2 (Treutlein et al. 2009). However, a
recent GWAS of 1,897 European-American and African-American subjects with
alcohol dependence compared with 1,932 unrelated, alcohol-exposed, nondependent
controls did not replicate the finding reported by Treutlein and colleagues (Bierut et
al. 2010). Interestingly, Bierut’s GWAS found SNPs genotyped in GABRA2 that
overlap with SNPs reported by Edenberg et al. (2004).
The level of reaction to alcohol has been a useful tool to indicate a possible
increase in susceptibility to alcoholism. Studies have found a correlation between level
of response (LR) to alcohol and the risk of developing alcohol dependency (Schuckit
1999). Numerous alcoholics have reported an ability to consume large amounts of
alcohol with relatively little effect from early in their drinking careers (Schuckit 1999).
A low LR is usually evaluated by giving alcohol to individuals and determining the
intensity of response at a given blood alcohol concentration (BAC), or by indirectly
measured through a self-report of a history of a higher number of drinks required to
produce a specific effect (Schuckit 2000). A study of 453 sons of alcoholics and
controls as conducted over a period of 15 years demonstrated that a low LR was a
significant predictor of later alcoholism (Schuckit and Smith 1996).
There are several indications that LR is genetically influenced. For example, a
study on 3,810 adult twin pairs reported a higher level of similarity on some aspects of
LR in identical twins than in fraternal twins, with an estimated heritability between 40
and 60 percent (Martin 1988). A pilot study (Mazzanti et al. 1999) evaluated 17 men
with low LR scores, comparing results to 24 individuals who were clearly higher on
the LR scale. The high LR and low LR groups were then evaluated for the patterns of
5 candidate genes relating to serotonin and gamma-aminobutyric acid functions. The
14 men with the LL genotype of the serotonin transporter (5-HTT) polymorphism and
the seven with the genotype of the GABAA alpha 6 polymorphism had demonstrated
lower LR scores at about age 20, and had significantly higher proportions of alcoholics
than the other genotypes for those loci. These studies show that low LR can be a
potential indicator to a genetic risk of alcoholism.

CONCLUSION
In conclusion, evidence has shown that there exists a genetic susceptibility to
alcoholism. However, it is clear that there are environmental factors, possible as high
as 50% (Dick and Beirut 2006), that can attribute to alcoholism. The main focus of
this paper is to show that the genetic component of alcoholism exists as well, though it
is clear that alcoholism is a complex disease that involves various mechanisms and
pathways. Susceptibility to alcoholism cannot be attributed to one single gene,
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neurotransmitter, or receptor. Other possible neurotransmitters that haven’t been
discussed but yet can play a vital role are serotonin and dopamine (DRD2). This
paper is only a brief overview of possible genetic contributions to alcoholism. There is
much more research that has been done and more that will be done in the near future.
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